Trial Profile
Protecting Households On Exposure to Newly Diagnosed Index Multidrug-Resistant Tuberculosis Patients (PHOENIx MDR-TB)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Oct 2023
Price :
$35
*
At a glance
- Drugs Delamanid (Primary) ; Isoniazid (Primary) ; Pyridoxine
- Indications Pulmonary tuberculosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms PHOENIx MDR-TB
- 02 Nov 2021 Planned End Date changed from 15 Oct 2025 to 30 Sep 2026.
- 02 Nov 2021 Planned primary completion date changed from 15 Oct 2025 to 30 Sep 2026.
- 22 Mar 2021 Planned End Date changed from 18 Jun 2025 to 15 Oct 2025.